Home NDC 65757-653 LYBALVI
Product NDC 65757-653
11-digit product format 657570653
Labeler code 65757
Product ID 65757-653_44ae69cc-b9a6-4658-90fa-1dbef1e97eb4
Type HUMAN PRESCRIPTION DRUG
Nonproprietary name olanzapine and samidorphan L-malate
Dosage form TABLET, FILM COATED
Route ORAL
Labeler Alkermes, Inc.
Application NDA213378
Marketing category NDA
Marketing start 2021-09-20
Substance OLANZAPINE; SAMIDORPHAN L-MALATE
Active strength 15; 10 mg/1; mg/1
Pharmacologic classes Atypical Antipsychotic [EPC], Opioid Antagonist [EPC], Opioid Antagonists [MoA]
NDC exclude flag No
Listing certified through 2027-12-31
Current FDA listing Yes Observed NDC auxiliary status history# This history shows the information present in each captured FDA auxiliary file. It is not a continuous regulatory timeline, and a missing record does not establish a status.
Historic NDC status page 1 of 1 · 30 matching rows.
View current auxiliary records. · View the auxiliary file history.
Captured / source date, Dataset, Scope table Captured / source date Dataset Scope Package NDC Snapshot Source SHA-256 2025-12-14 21:27 UTC · source 2025-12-05 unfinished product product a6255e0c9aa5…a0211a219f2e…2025-12-14 21:27 UTC · source 2025-12-05 unfinished package package 65757-653-03 a6255e0c9aa5…a0211a219f2e…2025-08-26 23:59 UTC · source 2025-08-26 unfinished product product 1d862106b807…00c93037cd84…2025-08-26 23:59 UTC · source 2025-08-26 unfinished package package 65757-653-03 1d862106b807…00c93037cd84…2025-05-15 14:59 UTC · source 2025-05-14 unfinished product product 390b4c401c3f…2c692c2daee3…2025-05-15 14:59 UTC · source 2025-05-14 unfinished package package 65757-653-03 390b4c401c3f…2c692c2daee3…2025-04-01 07:37 UTC · source 2025-03-31 unfinished product product e30019b0c005…a3f0b14938b7…2025-04-01 07:37 UTC · source 2025-03-31 unfinished package package 65757-653-03 e30019b0c005…a3f0b14938b7…2025-03-01 13:19 UTC · source 2025-02-28 unfinished product product bbbc9f937eca…946b9c97cf81…2025-03-01 13:19 UTC · source 2025-02-28 unfinished package package 65757-653-03 bbbc9f937eca…946b9c97cf81…2025-02-27 05:24 UTC · source 2025-02-26 unfinished product product f268b84574a6…26285f5ac5df…2025-02-27 05:24 UTC · source 2025-02-26 unfinished package package 65757-653-03 f268b84574a6…26285f5ac5df…2025-02-01 13:13 UTC · source 2025-01-31 unfinished product product f764e8902f78…92046438deef…2025-02-01 13:13 UTC · source 2025-01-31 unfinished package package 65757-653-03 f764e8902f78…92046438deef…2025-01-20 13:05 UTC · source 2025-01-17 unfinished product product 68b1e3bced9e…98a755eb8bc6…2025-01-20 13:05 UTC · source 2025-01-17 unfinished package package 65757-653-03 68b1e3bced9e…98a755eb8bc6…2024-11-29 20:42 UTC · source 2024-11-29 unfinished product product 05c55d027831…ca05dca9dc4c…2024-11-29 20:42 UTC · source 2024-11-29 unfinished package package 65757-653-03 05c55d027831…ca05dca9dc4c…2024-11-09 02:36 UTC · source 2024-11-08 unfinished product product 48b4f40e6753…c7c7a00d2afa…2024-11-09 02:36 UTC · source 2024-11-08 unfinished package package 65757-653-03 48b4f40e6753…c7c7a00d2afa…2024-10-09 02:27 UTC · source 2024-10-08 unfinished product product 27f29a85d7e4…1372111e901f…2024-10-09 02:27 UTC · source 2024-10-08 unfinished package package 65757-653-03 27f29a85d7e4…1372111e901f…2024-07-10 04:00 UTC · source 2024-07-09 unfinished product product 8d62ce987f31…9fe9ef23e30d…2024-07-10 04:00 UTC · source 2024-07-09 unfinished package package 65757-653-03 8d62ce987f31…9fe9ef23e30d…2024-05-28 21:11 UTC · source 2024-05-28 unfinished product product d1e113ab4d42…063ee3eb0a1d…2024-05-28 21:11 UTC · source 2024-05-28 unfinished package package 65757-653-03 d1e113ab4d42…063ee3eb0a1d…2024-05-15 03:51 UTC · source 2024-05-14 unfinished product product 50b4072663b7…eae3003ed65e…2024-05-15 03:51 UTC · source 2024-05-14 unfinished package package 65757-653-03 50b4072663b7…eae3003ed65e…2022-04-09 23:13 UTC · source 2022-04-08 unfinished product product 906f6e251498…bf70b80e44f0…2022-04-09 23:13 UTC · source 2022-04-08 unfinished package package 65757-653-03 906f6e251498…bf70b80e44f0…
Source provenance: Browse the complete Orange Book source catalog · source snapshot 42 .
Orange Book products# Current product rows page 1 of 1 · 4 matching rows.
Application-product, Trade name, Ingredient table Application-product Trade name Ingredient Strength Dosage form / route TE codes RLD / RS Approval date N213378-001 LYBALVI OLANZAPINE; SAMIDORPHAN L-MALATE 5MG;EQ 10MG BASE TABLET / ORAL RLD, RS 2021-05-28 N213378-002 LYBALVI OLANZAPINE; SAMIDORPHAN L-MALATE 10MG;EQ 10MG BASE TABLET / ORAL RLD 2021-05-28 N213378-003 LYBALVI OLANZAPINE; SAMIDORPHAN L-MALATE 15MG;EQ 10MG BASE TABLET / ORAL RLD 2021-05-28 N213378-004 LYBALVI OLANZAPINE; SAMIDORPHAN L-MALATE 20MG;EQ 10MG BASE TABLET / ORAL RLD 2021-05-28
Orange Book patents# Current patent rows page 1 of 2 · 84 matching rows.
Orange Book exclusivity# Current exclusivity rows page 1 of 1 · 4 matching rows.
Observed Orange Book product history# Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.
Product history page 1 of 4 · 136 observed states.
Captured, Edition, Application-product table Captured Edition Application-product Trade name Strength Dosage form / route Product TE source text RLD / RS Approval date Source SHA-256 2026-08-18 06:07:40 2026-07 N213378-001 LYBALVI 5MG;EQ 10MG BASE TABLET / ORAL RLD, RS 2021-05-28 caaa826d4ba7…2026-08-18 06:07:40 2026-07 N213378-002 LYBALVI 10MG;EQ 10MG BASE TABLET / ORAL RLD 2021-05-28 caaa826d4ba7…2026-08-18 06:07:40 2026-07 N213378-003 LYBALVI 15MG;EQ 10MG BASE TABLET / ORAL RLD 2021-05-28 caaa826d4ba7…2026-08-18 06:07:40 2026-07 N213378-004 LYBALVI 20MG;EQ 10MG BASE TABLET / ORAL RLD 2021-05-28 caaa826d4ba7…2026-02-19 14:30 UTC 2026-02 N213378-001 LYBALVI 5MG;EQ 10MG BASE TABLET / ORAL RLD, RS 2021-05-28 011fe1cb6892…2026-02-19 14:30 UTC 2026-02 N213378-002 LYBALVI 10MG;EQ 10MG BASE TABLET / ORAL RLD 2021-05-28 011fe1cb6892…2026-02-19 14:30 UTC 2026-02 N213378-003 LYBALVI 15MG;EQ 10MG BASE TABLET / ORAL RLD 2021-05-28 011fe1cb6892…2026-02-19 14:30 UTC 2026-02 N213378-004 LYBALVI 20MG;EQ 10MG BASE TABLET / ORAL RLD 2021-05-28 011fe1cb6892…2025-12-14 10:44 UTC · 2 captures of this ZIP 2025-12 N213378-001 LYBALVI 5MG;EQ 10MG BASE TABLET / ORAL RLD, RS 2021-05-28 31067a03dcf5…2025-12-14 10:44 UTC · 2 captures of this ZIP 2025-12 N213378-002 LYBALVI 10MG;EQ 10MG BASE TABLET / ORAL RLD 2021-05-28 31067a03dcf5…2025-12-14 10:44 UTC · 2 captures of this ZIP 2025-12 N213378-003 LYBALVI 15MG;EQ 10MG BASE TABLET / ORAL RLD 2021-05-28 31067a03dcf5…2025-12-14 10:44 UTC · 2 captures of this ZIP 2025-12 N213378-004 LYBALVI 20MG;EQ 10MG BASE TABLET / ORAL RLD 2021-05-28 31067a03dcf5…2025-08-23 18:47 UTC 2025-08 N213378-001 LYBALVI 5MG;EQ 10MG BASE TABLET / ORAL RLD, RS 2021-05-28 6a471c1ec25d…2025-08-23 18:47 UTC 2025-08 N213378-002 LYBALVI 10MG;EQ 10MG BASE TABLET / ORAL RLD 2021-05-28 6a471c1ec25d…2025-08-23 18:47 UTC 2025-08 N213378-003 LYBALVI 15MG;EQ 10MG BASE TABLET / ORAL RLD 2021-05-28 6a471c1ec25d…2025-08-23 18:47 UTC 2025-08 N213378-004 LYBALVI 20MG;EQ 10MG BASE TABLET / ORAL RLD 2021-05-28 6a471c1ec25d…2025-03-22 03:13 UTC · 3 captures of this ZIP 2025-03 N213378-001 LYBALVI 5MG;EQ 10MG BASE TABLET / ORAL RLD, RS 2021-05-28 fd3edfee7708…2025-03-22 03:13 UTC · 3 captures of this ZIP 2025-03 N213378-002 LYBALVI 10MG;EQ 10MG BASE TABLET / ORAL RLD 2021-05-28 fd3edfee7708…2025-03-22 03:13 UTC · 3 captures of this ZIP 2025-03 N213378-003 LYBALVI 15MG;EQ 10MG BASE TABLET / ORAL RLD 2021-05-28 fd3edfee7708…2025-03-22 03:13 UTC · 3 captures of this ZIP 2025-03 N213378-004 LYBALVI 20MG;EQ 10MG BASE TABLET / ORAL RLD 2021-05-28 fd3edfee7708…2025-02-26 10:13 UTC · 3 captures of this ZIP 2025-02 N213378-001 LYBALVI 5MG;EQ 10MG BASE TABLET / ORAL RLD, RS 2021-05-28 b8a1b40f171c…2025-02-26 10:13 UTC · 3 captures of this ZIP 2025-02 N213378-002 LYBALVI 10MG;EQ 10MG BASE TABLET / ORAL RLD 2021-05-28 b8a1b40f171c…2025-02-26 10:13 UTC · 3 captures of this ZIP 2025-02 N213378-003 LYBALVI 15MG;EQ 10MG BASE TABLET / ORAL RLD 2021-05-28 b8a1b40f171c…2025-02-26 10:13 UTC · 3 captures of this ZIP 2025-02 N213378-004 LYBALVI 20MG;EQ 10MG BASE TABLET / ORAL RLD 2021-05-28 b8a1b40f171c…2025-01-19 17:59 UTC · 7 captures of this ZIP 2025-01 N213378-001 LYBALVI 5MG;EQ 10MG BASE TABLET / ORAL RLD, RS 2021-05-28 03ed91905a0d…2025-01-19 17:59 UTC · 7 captures of this ZIP 2025-01 N213378-002 LYBALVI 10MG;EQ 10MG BASE TABLET / ORAL RLD 2021-05-28 03ed91905a0d…2025-01-19 17:59 UTC · 7 captures of this ZIP 2025-01 N213378-003 LYBALVI 15MG;EQ 10MG BASE TABLET / ORAL RLD 2021-05-28 03ed91905a0d…2025-01-19 17:59 UTC · 7 captures of this ZIP 2025-01 N213378-004 LYBALVI 20MG;EQ 10MG BASE TABLET / ORAL RLD 2021-05-28 03ed91905a0d…2024-12-13 21:23 UTC · 2 captures of this ZIP 2024-12 N213378-001 LYBALVI 5MG;EQ 10MG BASE TABLET / ORAL RLD, RS 2021-05-28 2680178bc6a6…2024-12-13 21:23 UTC · 2 captures of this ZIP 2024-12 N213378-002 LYBALVI 10MG;EQ 10MG BASE TABLET / ORAL RLD 2021-05-28 2680178bc6a6…2024-12-13 21:23 UTC · 2 captures of this ZIP 2024-12 N213378-003 LYBALVI 15MG;EQ 10MG BASE TABLET / ORAL RLD 2021-05-28 2680178bc6a6…2024-12-13 21:23 UTC · 2 captures of this ZIP 2024-12 N213378-004 LYBALVI 20MG;EQ 10MG BASE TABLET / ORAL RLD 2021-05-28 2680178bc6a6…2024-09-14 05:58 UTC · 2 captures of this ZIP 2024-09 N213378-001 LYBALVI 5MG;EQ 10MG BASE TABLET / ORAL RLD, RS 2021-05-28 5bbf6a4d5a75…2024-09-14 05:58 UTC · 2 captures of this ZIP 2024-09 N213378-002 LYBALVI 10MG;EQ 10MG BASE TABLET / ORAL RLD 2021-05-28 5bbf6a4d5a75…2024-09-14 05:58 UTC · 2 captures of this ZIP 2024-09 N213378-003 LYBALVI 15MG;EQ 10MG BASE TABLET / ORAL RLD 2021-05-28 5bbf6a4d5a75…2024-09-14 05:58 UTC · 2 captures of this ZIP 2024-09 N213378-004 LYBALVI 20MG;EQ 10MG BASE TABLET / ORAL RLD 2021-05-28 5bbf6a4d5a75…2024-11-08 22:44 UTC · 3 captures of this ZIP 2024-11 N213378-001 LYBALVI 5MG;EQ 10MG BASE TABLET / ORAL RLD, RS 2021-05-28 d8e5a09893c0…2024-11-08 22:44 UTC · 3 captures of this ZIP 2024-11 N213378-002 LYBALVI 10MG;EQ 10MG BASE TABLET / ORAL RLD 2021-05-28 d8e5a09893c0…2024-11-08 22:44 UTC · 3 captures of this ZIP 2024-11 N213378-003 LYBALVI 15MG;EQ 10MG BASE TABLET / ORAL RLD 2021-05-28 d8e5a09893c0…2024-11-08 22:44 UTC · 3 captures of this ZIP 2024-11 N213378-004 LYBALVI 20MG;EQ 10MG BASE TABLET / ORAL RLD 2021-05-28 d8e5a09893c0…
Observed Orange Book patent history# Patent history page 1 of 62 · 2,444 observed states.
Captured, Edition, Application-product table Captured Edition Application-product Patent Expiration Use code Coverage / status Submission date Source SHA-256 2026-08-18 06:07:40 2026-07 N213378-001 10716785 2031-08-23 U-3136 2021-06-25 caaa826d4ba7…2026-08-18 06:07:40 2026-07 N213378-001 10716785 2031-08-23 U-3137 2021-06-25 caaa826d4ba7…2026-08-18 06:07:40 2026-07 N213378-001 11185541 2031-08-23 U-3140 2021-12-22 caaa826d4ba7…2026-08-18 06:07:40 2026-07 N213378-001 11241425 2031-08-23 U-3137 2022-03-03 caaa826d4ba7…2026-08-18 06:07:40 2026-07 N213378-001 11351166 2031-08-23 U-3140 2022-07-11 caaa826d4ba7…2026-08-18 06:07:40 2026-07 N213378-001 11351166 2031-08-23 U-3141 2022-07-11 caaa826d4ba7…2026-08-18 06:07:40 2026-07 N213378-001 11793805 2031-08-23 U-3734 2023-11-13 caaa826d4ba7…2026-08-18 06:07:40 2026-07 N213378-001 12194035 2031-08-23 U-3141 2025-01-31 caaa826d4ba7…2026-08-18 06:07:40 2026-07 N213378-001 9126977 2031-08-23 U-3136 Drug product 2021-06-25 caaa826d4ba7…2026-08-18 06:07:40 2026-07 N213378-001 9126977 2031-08-23 U-3137 Drug product 2021-06-25 caaa826d4ba7…2026-08-18 06:07:40 2026-07 N213378-001 9517235 2031-08-23 U-3139 2021-06-25 caaa826d4ba7…2026-08-18 06:07:40 2026-07 N213378-001 9517235 2031-08-23 U-3138 2021-06-25 caaa826d4ba7…2026-08-18 06:07:40 2026-07 N213378-001 9119848 2031-08-30 Drug substance 2021-06-25 caaa826d4ba7…2026-08-18 06:07:40 2026-07 N213378-001 8778960 2032-02-13 U-3136 2021-06-25 caaa826d4ba7…2026-08-18 06:07:40 2026-07 N213378-001 8778960 2032-02-13 U-3137 2021-06-25 caaa826d4ba7…2026-08-18 06:07:40 2026-07 N213378-001 10300054 2033-05-31 U-3140 Drug product 2021-06-25 caaa826d4ba7…2026-08-18 06:07:40 2026-07 N213378-001 10300054 2033-05-31 U-3141 Drug product 2021-06-25 caaa826d4ba7…2026-08-18 06:07:40 2026-07 N213378-001 11707466 2041-11-12 Drug product 2023-08-23 caaa826d4ba7…2026-08-18 06:07:40 2026-07 N213378-001 11951111 2041-11-12 U-3886 2024-04-24 caaa826d4ba7…2026-08-18 06:07:40 2026-07 N213378-001 11951111 2041-11-12 U-3887 2024-04-24 caaa826d4ba7…2026-08-18 06:07:40 2026-07 N213378-001 12390474 2041-11-12 Drug product 2025-08-19 caaa826d4ba7…2026-08-18 06:07:40 2026-07 N213378-002 10716785 2031-08-23 U-3137 2021-06-25 caaa826d4ba7…2026-08-18 06:07:40 2026-07 N213378-002 10716785 2031-08-23 U-3136 2021-06-25 caaa826d4ba7…2026-08-18 06:07:40 2026-07 N213378-002 11185541 2031-08-23 U-3140 2021-12-22 caaa826d4ba7…2026-08-18 06:07:40 2026-07 N213378-002 11241425 2031-08-23 U-3137 2022-03-03 caaa826d4ba7…2026-08-18 06:07:40 2026-07 N213378-002 11351166 2031-08-23 U-3140 2022-07-11 caaa826d4ba7…2026-08-18 06:07:40 2026-07 N213378-002 11351166 2031-08-23 U-3141 2022-07-11 caaa826d4ba7…2026-08-18 06:07:40 2026-07 N213378-002 11793805 2031-08-23 U-3734 2023-11-13 caaa826d4ba7…2026-08-18 06:07:40 2026-07 N213378-002 12194035 2031-08-23 U-3141 2025-01-31 caaa826d4ba7…2026-08-18 06:07:40 2026-07 N213378-002 9126977 2031-08-23 U-3137 Drug product 2021-06-25 caaa826d4ba7…2026-08-18 06:07:40 2026-07 N213378-002 9126977 2031-08-23 U-3136 Drug product 2021-06-25 caaa826d4ba7…2026-08-18 06:07:40 2026-07 N213378-002 9517235 2031-08-23 U-3138 2021-06-25 caaa826d4ba7…2026-08-18 06:07:40 2026-07 N213378-002 9517235 2031-08-23 U-3139 2021-06-25 caaa826d4ba7…2026-08-18 06:07:40 2026-07 N213378-002 9119848 2031-08-30 Drug substance 2021-06-25 caaa826d4ba7…2026-08-18 06:07:40 2026-07 N213378-002 8778960 2032-02-13 U-3136 2021-06-25 caaa826d4ba7…2026-08-18 06:07:40 2026-07 N213378-002 8778960 2032-02-13 U-3137 2021-06-25 caaa826d4ba7…2026-08-18 06:07:40 2026-07 N213378-002 10300054 2033-05-31 U-3141 Drug product 2021-06-25 caaa826d4ba7…2026-08-18 06:07:40 2026-07 N213378-002 10300054 2033-05-31 U-3140 Drug product 2021-06-25 caaa826d4ba7…2026-08-18 06:07:40 2026-07 N213378-002 11707466 2041-11-12 Drug product 2023-08-23 caaa826d4ba7…2026-08-18 06:07:40 2026-07 N213378-002 11951111 2041-11-12 U-3886 2024-04-24 caaa826d4ba7…
Observed Orange Book exclusivity history# Exclusivity history page 1 of 4 · 136 observed states.
Additional Listing Data#
Finished product Yes
Brand name base LYBALVI
Listing expiration 2027-12-31 Active Ingredients# Ingredient, Strength table Ingredient Strength OLANZAPINE 15 mg/1 SAMIDORPHAN L-MALATE 10 mg/1
Harmonized UNII identifiers# UNII identifiers page 1 of 1 · 2 matching rows.
Identifier, FDA.report destination table Identifier FDA.report destination 0AJQ5N56E0 Internal UNII lookup N7U69T4SZR Internal UNII lookup
Harmonized RxCUI identifiers# RxCUI identifiers page 1 of 1 · 8 matching rows.
Identifier, FDA.report destination table Identifier FDA.report destination 2570392 Internal RxNorm lookup 2570398 Internal RxNorm lookup 2570399 Internal RxNorm lookup 2570401 Internal RxNorm lookup 2570402 Internal RxNorm lookup 2570404 Internal RxNorm lookup 2570405 Internal RxNorm lookup 2570407 Internal RxNorm lookup
Harmonized SPL set identifiers# SPL set identifiers page 1 of 1 · 1 matching rows.
DailyMed Product Concepts# DailyMed Package Descriptions# Package NDC, Product, Description table Package NDC Product Description Form Quantity Strength SPL version 65757-653-40 LYBALVI 1 in 1 CARTON TABLET, FILM COATED 1 16 65757-653-40 LYBALVI 7 in 1 BOTTLE TABLET, FILM COATED 7 16 65757-653-41 LYBALVI 1 in 1 CARTON TABLET, FILM COATED 1 16 65757-653-41 LYBALVI 7 in 1 BOTTLE TABLET, FILM COATED 7 16 65757-653-42 LYBALVI 1 in 1 CARTON TABLET, FILM COATED 1 16 65757-653-42 LYBALVI 30 in 1 BOTTLE TABLET, FILM COATED 30 16 65757-653-44 LYBALVI 90 in 1 BOTTLE TABLET, FILM COATED 90 16 65757-653-44 LYBALVI 1 in 1 CARTON TABLET, FILM COATED 1 16
DailyMed Dashboard NDC Coverage# NDC, Dashboard title, SPL version table NDC Dashboard title SPL version Validation Dashboard ZIP 65757-653 LYBALVI (OLANZAPINE AND SAMIDORPHAN L-MALATE) TABLET, FILM COATED [ALKERMES, INC.] 13 Current NDC, Legacy NDC, 8 package rows 20250316_32ffddd1-4e2b-45d9-9b36-bb730167ec80.zip
openFDA label cross-check# OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
Matched openFDA labels page 1 of 1 · 1 matching rows.
Brand, Generic, Manufacturer table Brand Generic Manufacturer SPL set ID Effective date Available safety fields Join LYBALVI OLANZAPINE AND SAMIDORPHAN L-MALATE Alkermes, Inc. 32ffddd1-4e2b-45d9-9b36-bb730167ec80 2026-01-31 Boxed warning, Warnings, Adverse reactions Exact identifier application applno (NDA): 213378 application number: NDA213378 ndc (product): 65757-653
DailyMed RxNorm Mappings# Packages# Package NDC, 11-digit format, Description table Package NDC 11-digit format Description Units Marketing start Marketing end Sample Exclude flag Status 65757-653-03 65757065303 153846 TABLET, FILM COATED in 1 CONTAINER (65757-653-03) 28-MAY-21 Current 65757-653-40 65757065340 1 BOTTLE in 1 CARTON (65757-653-40) > 7 TABLET, FILM COATED in 1 BOTTLE 1 bottle 2021-09-20 0000-00-00 No No Current 65757-653-41 65757065341 1 BOTTLE in 1 CARTON (65757-653-41) / 7 TABLET, FILM COATED in 1 BOTTLE 1 bottle 2021-09-20 0000-00-00 Yes No Current 65757-653-42 65757065342 1 BOTTLE in 1 CARTON (65757-653-42) / 30 TABLET, FILM COATED in 1 BOTTLE 1 bottle 2021-09-20 0000-00-00 No No Current 65757-653-44 65757065344 1 BOTTLE in 1 CARTON (65757-653-44) > 90 TABLET, FILM COATED in 1 BOTTLE 1 bottle 2021-09-20 0000-00-00 No No Current